tbuckley/cabot-search huggingface dataset:
Analysis of Efficacy, Safety and Costs of Systemic Antifungal Agents in 159 Consecutive High-Risk Cancer Patients for the Establishment of Standardized Guidelines
Authors: Werner Neubauer, Martina Kleber, Alf Zerweck, Veronique Thierry, Alexandra Goebel, Beate Lubrich, Hartmut Bertz, Monika Engelhardt
Journal: Blood (2008)
REAL WORLD EVALUATION OF MAJOR BLEEDING RISK AND COSTS FOR ALL CAUSES AND BLEEDING-RELATED HEALTH SERVICES AMONG ELDERLY PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH APIXABAN OR WARFARIN
Authors: Steven Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Cutice, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
Journal: Journal of the American College of Cardiology (2017)
EFFECT OF GENE POLYMORPHISM OF CALPAIN-10 ON THE RISK OF HYPERTENSION IN JAPANESE POPULATION
Authors: Masahiko Eto, Masanobu Okayama, Taro Takeshima, Maki Kumada, Takanori Aonuma, Yosikazu Nakamura, Eiji Kajii
Journal: Journal of the American College of Cardiology (2017)
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Authors: Irene M. Ghobrial, Ashraf Z Badros, James J. Vredenburgh, Jeffrey Matous, Aaron M. Caola, Alexandra Savell, Patrick Henrick, Claudia E. Paba-Prada, Robert L. Schlossman, Jacob P. Laubach, Jacalyn Rosenblatt, Andrew Yee, Jeffrey S. Wisch, Charles M. Farber, Rodrigo O. Maegawa, Saad Z Usmani, Joseph Cappuccio, Bradley Rivotto, Kimberly Noonan, Kaitlen Reyes, Nikhil C. Munshi, Kenneth C. Anderson, Paul Richardson
Journal: Blood (2016)
Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.
Authors: Amita Patnaik, Patricia LoRusso, Howard A. Ball, Erkut Bahceci, Geoffrey Yuen, Kyriakos P. Papadopoulos, Muaiad Kittaneh, Anthony W. Tolcher
Journal: Journal of Clinical Oncology (2013)

2602 Background: ASP3026 (3026) is a selective, potent, ATP-competitive, small molecule oral inhibitor of ALK receptor tyrosine kinase that has not previously been tested in humans. A Phase 1 dose-escalation trial, using a 3+3 design, evaluating 3026 as an oral single agent was conducted to investigate PK (Day 1 and Day 28), safety and clinical activity in patients (pts) with advanced malignancies (excluding leukemias) of ECOG PS 2 or less. Methods: 3026 was administered under fasting conditions on a continuous schedule to pts in successive dose-escalating cohorts at doses ranging from 25 mg QD to 800 mg QD. Results: Thirty pts were enrolled into the dose escalation part of the study. The MTD was determined based on DLT data from cycle 1. Three DLTs were observed: grade 2 nausea and vomiting leading to dose reduction at 525 mg QD; grade 3 rash leading to dose reduction, and grade 3 ALT/AST increase leading to study withdrawal at 800 mg QD. The most common AEs were constipation, vomiting, diarrhea, nausea and abdominal pain, and all AEs were manageable and reversible. Median AUC and Cmax increased proportionally with dose from 25 mg QD to 800 mg QD. There was no evidence of non-linear PK at ASP3026 doses &gt;25 mg QD. The median terminal half-life was approximately 10 - 41 hours. Overall, A3026 appears well absorbed with median Tmax around 3 hours for both Day 1 and Day 28. Terminal T 1/2 appears adequate for one daily dosing with median values ranging from approximately 18 to 34 hours. Based on visual inspection of pre-dose (trough) values from Days 8, 15, 22, and 28 it appears that steady-state conditions are achieved by day 28. Conclusions: The MTD of 3026 is 525 mg QD. Treatment with 3026 resulted in a promising safety and PK profile in pts with advanced malignancies. Further evaluation of 3026 in pts with tumors harboring gene mutation or ALK fusion genes in the cohort expansion phase at the MTD is ongoing. Clinical trial information: NCT01401504.
Self-reported cognitive impairment in cancer patients: A URCC CCOP longitudinal study of 595 patients
Authors: S. Kohli, J. J. Griggs, P. Jean-Pierre, K. M. Mustian, J. A. Roscoe, J. L. Wade, J. Kuebler, E. Fishkin, G. R. Morrow
Journal: Journal of Clinical Oncology (2006)

8502 Background: Patients undergoing cancer treatment often report cognitive impairment, manifested as problems with concentration and memory. Such cognitive problems may be noticed only by the patient. The purpose of this multicenter longitudinal study was to investigate the frequency and severity of self-reported problems with memory and concentration over time. Methods: Patients undergoing treatment for solid tumors self-rated problems with memory and concentration using an 11-point Likert Scale (0 = Not present to 10 = “As bad as you can imagine”) at baseline before treatment began (T1), at their worst during treatment (T2), and at 6 months following treatment (T3). Any symptom level ≥ 7 was classified as “severe.” T-tests, paired or independent as appropriate, were used to examine differences in symptoms over time and between patients treated with and without chemotherapy. Results: Of 595 participants, 356 (60%) received chemotherapy, with or without radiation and 239 (40%) radiation alone. Concentration problems were reported by 48% of all participants at T1 (5% severe), 67% at T2 (18% severe) and 58% (8% severe) at T3 (p &lt; .001). Memory loss was reported by 53% at T1 (4% severe), 67% (18% severe) at T2 and 68% (11% severe) at T3 (p &lt; .001). The average frequency and severity of both symptoms in patients receiving chemotherapy increased significantly between T1 and T2 (p&lt;.001). Both symptoms were less severe in patients receiving radiation alone at all three measurements (all ps&lt;.001). Symptoms at T3 were significantly higher than T1 for both groups (p&lt;.001). Conclusion: Self-reported problems with memory and concentration are experienced by the majority of cancer patients who receive chemotherapy and radiation. The cognitive problems get worse during treatment and persist at least 6 months following. Controlled studies of interventions for problems of memory loss and concentration are warranted. Supported in part by a supplement from the Division of Cancer Control and Population Sciences, NCI, to Public Health Service grant U10 CA37420 and by NCI grant 1R25CA102618. No significant financial relationships to disclose.
Pleiotrophin Secreted from Human Breast Cancer MCF-7-Ptn Cells Activates Stromal Fibroblasts, Induces Epithelial Island Formation, and Remodels the Microenvironment.
Authors: Masahiko Zuka, Yunchao Chang, Zhaoyi Wang, James R. Berenson, Thomas F. Deuel
Journal: Blood (2006)
Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
Authors: M. Beeram, E. K. Rowinsky, G. R. Weiss, S. Syed, A. Mita, A. Patnaik, M. Mita, M. Goldston, J. S. De Bono, A. W. Tolcher
Journal: Journal of Clinical Oncology (2004)

3050
Preclinical Activity of Splicing Modulators in U2AF1 Mutant MDS/AML
Authors: Cara Lunn Shirai, Manorama Tripathi, James N Ley, Matthew Ndonwi, Brian S White, Roberto Tapia, Borja Saez, Amy Bertino, Jin Shao, Sanghyun Kim, Thomas R Webb, Timothy A. Graubert, Matthew J. Walter
Journal: Blood (2015)
Efficacy of an enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenografts.
Authors: Jasmien Cornillie, Agnieszka Wozniak, Lise Vreys, Jasmien Wellens, Peter Pokreisz, Daphne Hompes, Maria Debiec-Rychter, Raf Sciot, Patrick Schoffski
Journal: Journal of Clinical Oncology (2015)

e13539 Background: DDLPS and SynSa are aggressive mesenchymal tumors with limited sensitivity to the standard-of-care treatment doxorubicin (doxo). We evaluated the efficacy of PhAc-ALGP-doxorubicin (ALGP-doxo), a prodrug that is metabolized to doxo by peptidases in the tumor microenvironment and/or tumor cells, in two DDLPS and one SynSa patient-derived xenograft. Methods: NMRI mice (n = 24 for each model) were transplanted subcutaneously with human DDLPS (models UZLX-STS3 and -STS5) or SynSa (UZLX-STS7) and randomized as follows: control (vehicle), doxo (cumulative dose of 0.03 mmol/kg for UZLX-STS3; 0.04 mmol/kg for -STS5 and -STS7) or ALGP-doxo (1.2 mmol/kg). Treatments were administered via intraperitoneal pumps, continuously releasing drugs for 7 days. Half of the mice were sacrificed after 7 days of treatment; the remaining animals were monitored for another 14 days. Treatment efficacy was assessed by tumor volume, histology, immunohistochemistry for markers of proliferation (phospho-histone H3, Ki-67) and apoptosis (cleaved caspase 3), and Western blotting (WB). Statistical analysis was performed with Wilcoxon and Mann-Withney U-test. Results: Tumor volume in the control and doxo group increased steadily, while ALGP-doxo caused tumor volume stabilization in UZLX-STS3 and -STS5. The average relative tumor volume under ALGP-doxo in UZLX-STS7 decreased to 60.1% on day 7 (p < 0.001) and 4.6% on day 21 (p = 0.016) as compared to baseline. The prodrug induced a significant decrease in proliferation and increase in apoptosis on day 7 in all models. This was also observed on day 21 in UZLX-STS3 and -STS5, while in -STS7 the analysis was impossible as tumor tissue was replaced by fibroblasts. pHH3 decrease in ALGP-doxo treated UZLX-STS5 and -STS7 tumors was confirmed by WB. Conclusions: ALGP-doxo shows considerably higher antitumor activity than doxo in patient-derived DDLPS and SynSa xenografts. The delivery of a 30-40 fold higher dose of ALGP-doxo than doxo is tolerated, while a comparable dose of doxo is lethal. These results warrant further testing in anthracycline-sensitive and -resistant preclinical models of human malignancies.
CLINICAL PRESENTATION, NATURAL HISTORY AND MANAGEMENT OF CORONARY ARTERY ECTASIA
Authors: Prasad C. Gunasekaran, Reza Masoomi, Dusan Stanojevic, Taylor Drees, John Fritzlen, Megan Haghnegahdar, Matthew McCullough, Ashwani Mehta, Matthew Earnest, Mark Wiley, Eric Hockstad, Peter Tadros, Kamal Gupta
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF LEFT ATRIAL APPENDAGE OCCLUSION ON LEFT ATRIAL FUNCTION
Authors: Venkat Lakshmi Kishan Vuddanda, Mohammad-Ali Jazayeri, Ling Li, Mohit Turagam, Srikanth Yandrapalli, Madhav Lavu, Valay Parikh, Donita Atkins, Madhu Reddy, Dhanunjaya Lakkireddy, Shelby Kutty
Journal: Journal of the American College of Cardiology (2017)
Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC).
Authors: Ryul Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Jin Ho Kim, Jin Chul Paeng, Se-Hoon Lee, Tack-Kyun Kwon, Dong-Wan Kim, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo, J. Hun Hah, Seong Keun Kwon
Journal: Journal of Clinical Oncology (2015)

6052 Background: The accuracy of 18F-fluorodeoxygluocose positron emission tomography/computed tomography (PET/CT) for predicting immediate failure after radical chemoradiotherapy (CRT) in HNSCC remains poorly characterized. The purpose of this study was to evaluate 1) predictive and prognostic values of PET/CT for immediate failure after CRT, and 2) their impact on clinical decision making for salvage surgery. Methods: From 2005 to 2013, medical records of 132 consecutive LA-HNSCC patients who received radical CRT were analyzed. PET/CTs were taken before CRT and 3-months after CRT. Immediate failure was defined residual disease or locoregional/ systemic relapse within one year. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of SUV for predicting immediate failure were estimated. Overall survival (OS) of patients who had/had not salvage surgery according to SUV were compared. Results: Of the 132 patients, 71 (53.8%) achieved metabolic complete response (mCR) in post CRT PET/CT. mCR group had better OS comparing with non-mCR group (3-year OS rate 95.8% vs. 66.6%, P < 0.001), as well as progression-free survival (PFS) (3-year PFS rate 89.5% vs. 56.9%, P < 0.001). Immediate failure occurred in 4/71 patients with mCR, 24/61 patients with non-mCR (P < 0.001). Among the various metabolic values, the post CRT maximum SUV (postSUVmax) was found to be optimal for predicting immediate failure with corresponding cutoff point of 3.9. The area under the receiver operating curve was 0.82 (95% confidence interval [CI] 0.73-0.92). The sensitivity, specificity, NPV, and PPV were 71.4%, 83.7%, 91.6%, and 54.1%, respectively. Salvage surgery was conducted in 9 of 37 patients with postSUVmax ≥ 3.9. There was no significant difference in OS by immediate salvage surgery based on post CRT PET/CT compared with no immediate salvage operation (3-year OS rate 66.7% vs. 58.1%, P = 0.719). Conclusions: Post CRT PET/CT has prognostic value for OS and is useful for predicting immediate failure with high NPV. However, early detection of immediate failure and salvage surgery based on post CRT PET/CT does not seem to lead OS benefit.
Evaluating cardiovascular and gastrointestinal risks and benefits of COX-2 selective inhibitors and non-selective nsaids in osteoarthritis patients using a decision analytic model
Authors: N Mittmann, N Risebrough, Ernest Choy, S Knowles, C Chen, A Lising, T Almeida, T Koncz, L Niculescu
Journal: Annals of the Rheumatic Diseases (2007)
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling
Authors: Mirjam Blattner, Deli Liu, Brian D. Robinson, Dennis Huang, Anton Poliakov, Dong Gao, Srilakshmi Nataraj, Lesa D. Deonarine, Michael A. Augello, Verena Sailer, Lalit Ponnala, Michael Ittmann, Arul M. Chinnaiyan, Andrea Sboner, Yu Chen, Mark A. Rubin, Christopher E. Barbieri
Journal: Cancer Cell (2017)
EARLY UNLOADING WITH IMPELLA SUPPORT IN ACUTE MI WITH CARDIOGENIC SHOCK LINKED TO DECREASED INFARCT SIZE, IN-HOSPITAL MORTALITY, AND HOSPITAL LENGTH OF STAY
Authors: Shailendra Singh, Yonathon Litwok, Evelina Grayver, Stacey Rosen, Alexander Lee
Journal: Journal of the American College of Cardiology (2017)
RADIATION EXPOSURE AMONG NON-PHYSICIAN STAFF MEMBERS DURING CARDIAC CATHETERIZATION AND THE IMPACT OF PROACTIVE SHIELDING
Authors: Austin Clarey, Jacob Bundy, Edwin Mandieka, Andrew LaCombe, Thomas Crane, David Benavides, Matthew Elmore, Abbey Mulder, Jessica Parker, Jessica Campbell, Stacie Vanoosterhout, Ryan Madder
Journal: Journal of the American College of Cardiology (2017)
THE INFLAMMASOME PATHWAY IS ASSOCIATED WITH ADVERSE VENTRICULAR REMODELING FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Juyong Brian Kim, Yukari Kobayashi, Tatiana Kouznetsova, Kegan Moneghetti, Daniel Brenner, Ryan O'Malley, Catherine Dao, Ingela Schnittger, David Liang, Joseph Wu, Michael Fischbein, Anson Lee, D. Craig Miller, Alan Yeung, William Fearon, Francois Haddad
Journal: Journal of the American College of Cardiology (2017)
A novel live cell platform utilizing phenotypic biophysical and molecular biomarkers for assessing prostate cancer aggressiveness.
Authors: Kevin B. Knopf, Kimberly M. Rieger-Christ, Travis B. Sullivan, Naveen Kella, Ray Hernandez, Hani H. Rashid, Vladimir Mouraviev, Michael S. Manak, Wendell R. Su, Andrew Min, Delaney Berger, Brad J. Hogan, Robert J. Saphirstein, Matt J. Whitfield, Jonathan S. Varsanik, Mani Foroohar, David Albala, Ashok C. Chander, Grannum R. Sant
Journal: Journal of Clinical Oncology (2015)

e16031 Background: Overdiagnosis and overtreatment of prostate cancer is a problem that requires the need for a diagnostic test that can predict cancer aggressiveness and metastatic potential. Cellanyx Diagnostics has developed a new diagnostic utilizing matrix biology, cell culture, molecular & cellular biomarkers, microfluidics, and machine vision to fill this need. This study evaluated the ability to culture prostate cells from human prostate tissue samples, automate biomarker measurement from live and fixed cells, and objectively analyze multiple biomarkers through algorithmic analysis. Methods: Conditions were developed for reliably culturing primary cancer cells in vitro by simulating in vivo conditions on a specialized extra-cellular matrix. A microfluidic device was utilized to culture biopsy samples ex vivo to enable automated imaging of label-free and label-based, molecular and biophysical biomarkers. Machine vision software using grayscale value analysis and masking techniques measured a number of proprietary biomarkers of Oncogenic Potential (OP) and Metastatic Potential (MP). Results: Phenotypic, molecular, and biophysical biomarkers of cell morphology, cellular dynamics, protein localization, and protein dynamics were measured on live cells derived from prostate tissue samples (n = 100). OP and MP were calculated using unbiased machine vision algorithms. Concordance analysis demonstrated that OP & MP, derived from primary biomarkers, can distinguish normal from cancer cells and are potentially useful in distinguishing Gleason 6 and 7 with 80% specificity and 80% sensitivity. Conclusions: These findings represent the initial step in a clinical validation model that will demonstrate the capability of a live-cell in vitro diagnostic platform to generate objective scoring metrics of MP and OP to discriminate between low, intermediate, and high risk prostate cancer cells. This novel and unique diagnostic and predictive biomarker platform holds promise as a risk stratification tool in the management of prostate cancer.
CHANGING SPECTRUM OF INFECTIVE ENDOCARDITIS: REVIEW OF 707 PATIENTS OVER 26 YEARS
Authors: Fabio Chirillo, Federica Calabro', Alessandro De Leo, Alessandra Pedrocco, Francesco Tona, Federica Mondin, Giuseppe Minniti, Piergiorgio Scotton, Zoran Olivari
Journal: Journal of the American College of Cardiology (2017)
Diagnostic Power of Laser Assisted Optical Rotational Cell Analyzer (LoRRca MaxSis) Evaluated in 118 Patients Affected By Hereditary Hemolytic Anemias
Authors: Paola Bianchi, Anna Zaninoni, Elisa Fermo, Cristina Vercellati, Marcello Anna Paola, Alberto Zanella, Agostino Cortelezzi, Wilma Barcellini
Journal: Blood (2015)
Phase II study of paclitaxel and capecitabine (PX) combination as neoadjuvant chemotherapy for unresectable locally advanced gastric cancer.
Authors: Yoon Ho Ko, Sook Hee Hong, Sang Young Roh, Kyo Young Song, Eun Sun Jung, Hae Myung Jeon, Cho Hyun Park, Young Seon Hong
Journal: Journal of Clinical Oncology (2013)

e15164 Background: Unresectable locally advanced adenocarcinoma (AGC) of the stomach is associated with poor prognosis due to the lack of effective treatment. Neoadjuvant chemotherapy (NAC) has drawn more attention to the treatment of locally AGC in the current multidisciplinary treatment model. Paclitaxel and capecitabine (PX) has been used in palliative setting with good response rates but its role in a neoadjuvant setting is not well established. This phase II study was performed to evaluate the efficacy and safety of neoadjuvant PX chemotherapy in patients with unresectable locally AGC. Methods: Patients with AGC, clinically unresectable because of local invasion and/ or conglomerated regional lymph nodes (station 7, 8, and 9) metastasis on based on laparoscopic staging, were enrolled. PX consisted of paclitaxel 175 mg/m 2 i.v. on day 1, and capecitabine 835 mg/m 2 twice daily p.o. on days 1–14 every 21 days. After three cycles of NAC, patients with clinically resectable AGC underwent surgical resection. Results: This trial was stopped for poor accrual after 18 patients were enrolled; 50% patients had tumors located in the proximal third of the stomach. Seventeen patients finished three cycles of chemotherapy. The overall response rate was 41.2% (7/17 cases), of which 71.4% (10/14 cases) metabolic response. Fourteen (77.8%) of the 18 patients enrolled underwent surgery, and 12 (85.7%) had an R0 resection. Pathological complete response was observed in one (7.1%) of patients. Toxicity was mild to moderate and there were no treatment-related deaths and no major surgical complications. With a median follow-up of 28.6 months (range 6.4-38.4 months), the 2-year survival rate for all patients was 71.1%. Subgroup analysis found R0 resection (35.7 months vs. 20.6 months, P= 0.005) and patients with pathologic N downstaging (P &lt; 0.001) to have improved overall survival. Conclusions: Neoadjuvant chemotherapy with PX shows promising results in unresectable locally AGC patients without increased morbidity and mortality. Neoadjuvant PX may permit a larger chance of curative resection in unresectable locally AGC patients.
GESTATIONAL HYPERTENSION AND PREECLAMPSIA ARE ASSOCIATED WITH SUBCLINICAL LEFT VENTRICULAR SYSTOLIC AND DIASTOLIC DYSFUNCTION
Authors: Livia Florentina Trasca, Natalia Patrascu, Diana Mihalcea, Laura Lungeanu, Sorina Mihaila, Ramona Bruja, Manuela Neagu, Monica Cirstoiu, Simona Albu, Dragos Vinereanu
Journal: Journal of the American College of Cardiology (2017)
Retraction: CTL Activation Using the Natural Low-Affinity Epitope 222-229 from Tyrosinase-Related Protein 1 Leads to Tumor Rejection
Authors: Kevin Pavelko, Michael Hansen, Larry Pease
Journal: Cancer Research (2010)

CTL Activation Using the Natural Low-Affinity Epitope 222-229 from Tyrosinase-Related Protein 1 Leads to Tumor Rejection," which was published in the April 1, 2009 issue of Cancer Research (1).In the course of investigating suspicious patterns of experimental results in the laboratory, a systematic and in-depth study of key findings in this article was carried out using blind protocols.In these repeat studies, no evidence was found to support our original conclusions that B7-DCXAb modulates dendritic cell functions.We do not believe our failure to reproduce our earlier findings is the result of a technical problem.A member of the B7-DCXAb investigative team, Dr. Suresh Radhakrishnan, who was involved in or had access to all work on this subject, was found in a formal institutional investigation to have engaged in scientific misconduct in unpublished experiments by manipulating another investigator's experiment involving the B7-DCXAb reagent.This finding of misconduct together with our inability to reproduce key findings using blinded protocols has undermined our confidence in our published reports.We seek therefore to retract this body of work.